APRIL 16-18, 2019


The 6th Annual Translational Microbiome Conference is Coming Back to Boston in April 2020. 

Please check back in the coming weeks for additional details.

Arrowhead Announces the Preliminary Speaker Faculty for 3rd Annual Translational Microbiome Conference

November 16 2016 – Minneapolis, MN – Arrowhead Publishers has announced the preliminary speaking faculty for the 3rd Annual Translational Microbiome Conference. This conference, taking place April 11-13, 2017 in Boston, MA, will once again bring together the top companies in the microbiome space working to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products.

This year’s conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome industry will have to recognize and navigate in order to successfully commercialize their products. For more information on the conference, visit: http://www.microbiomeconference.com.

Speakers Include:

  • James Arbogast, Ph.D., VP of Hygiene Sciences and Public Health Advancements, GOJO Industries
  • JP Benya, VP Commercial, Assembly Biosciences
  • Carrie Brodmerkel, Ph.D., Senior Director, Systems Pharmacology & Biomarkers, Janssen R&D
  • Martha Carlin, Chief Executive Revolutionary, The BioCollective
  • Rodolphe Clerval, Chief Business Officer, Enterome
  • Rita Colwell, Ph.D., Distinguished Professor, Univ. of Maryland at College Park, Johns Hopkins Univ. Bloomberg School of Public Health, President, CosmosID, Inc., Senior Advisor, Canon U.S. Life Sciences, Inc.
  • Colleen Cutcliffe, Ph.D., Co-Founder and CEO, Whole Biome
  • Manoj Dadlani, Chief Executive Officer, CosmosID
  • Xavier Duportet, Chief Executive Officer, Eligo Biosciences
  • Jack Gilbert, Ph.D., Faculty Director, The Microbiome Center, Professor, Department of Surgery, The University of Chicago, Senior Scientist (Adjunct), The Marine Biological Laboratory, Group Leader in Microbial Ecology, Argonne National Laboratory
  • Wa’el Hashad, Executive VP and CCO, Seres Therapeutics
  • Mohan Iyer, Chief Business Officer, Second Genome
  • Lee Jones, Founder, President and CEO, Rebiotix
  • Colleen Kelly, MD, FACG, Gastroenterologist, Center for Women’s Gastrointestinal Medicine, Women’s Medicine Collaborative
  • Arpita Maiti, Ph.D., Director, External R&D Innnovation, Inflammation & Immunology, Pfizer
  • KT Moortgat, Ph.D., Chief Executive Officer, Osel
  • Bernat Olle, Ph.D., Chief Executive Officer, Vedanta Biosciences
  • Jack Oswald, Co-Founder, CTO and CEO, IsoThrive
  • Jackie Papkoff, Ph.D., SVP Research, Evelo Biosciences
  • Greg Sieczkiewicz, JD, Ph.D., Managing Director, Chief IP Counsel, MPM Capital
  • Larry Weiss, MD, Chief Medical Officer, AOBiome
  • James White, Ph.D., Founder, Resphera Biosciences

For more information, visit: http://www.microbiomeconference.com/brochure.

This year brings several exciting additions to the conference, designed to offer attendees insights that they can implement in their own organizations. First, this year’s conference will feature two parallel tracks on the second day, closely focused on the nutrition and consumer industries within the microbiome space.

In addition, the conference will offer hands-on, intensive pre-conference workshops to help attendees understand real-world issues and give them the tools to better address how these issues impact their businesses.

For more information, please contact:

John Waslif: Managing Director
Arrowhead Publishers
866-945-0263 ext 700
This email address is being protected from spambots. You need JavaScript enabled to view it.
Rachel Donlon: Marketing Associate
Arrowhead Publishers
866-945-0263 ext 701
This email address is being protected from spambots. You need JavaScript enabled to view it.


The Microbiome-Vaccine Summit: Microbiome-Mediated Immunity and the Future of Vaccines

Dates and Location: September 2019 | London, United Kingdom

Microbes in the gut have been found to exert profound control over the immune system. The role of the microbiome in modulating the immune response has already been substantially researched with numerous correlations between the microbiome’s immune effects and disease hypothesized and being explored. One exciting area of inquiry is the potential for the microbiome to play a substantial role in vaccine response. This area of exploration includes:

♦ Its potential to change how patients respond to checkpoint inhibition therapy for metastatic melanoma
♦ Correlations between the efficacy of the rotavirus and geographic differences in the gut biome
♦ How the antibiotic-mediated dysbiotic gut microbiome may actually mount a strong immune response to the seasonal flu vaccine
♦ And the gut-lung axis, or the role of the microbiome in the meteoric rise of asthma
♦ And even the possibility of explaining why some children experience adverse reactions to vaccinations, and why our current vaccine protocol starting within 12 hours of birth does not properly factor gut microbiota as crucial to immune response.

An extension of the highly successful Arrowhead Translational Microbiome Conference held every April in Boston, join us for this first event in our Translational Microbiome Spotlight series, where we bring together industry and academic experts considering the interface between the microbiome and vaccines in a one day, highly interactive roundtable forum.

CLICK HERE to request more information. If you are interested in speaking or sponsorship opportunities, please email This email address is being protected from spambots. You need JavaScript enabled to view it..